

Diseas Site	Study	Study Name	Open Date	Number of Active Institutions	Number of Current IRBs
BREAST	S0221	Breast,Adj,N+,ACvAC+G/Pac qlv2	01-NOV-03	310	133
	S0230	Breast,Adj,Chemo +/- Goserelin	01-OCT-03	137	57
	S0500	Brst,Adv,CTC,mntain v chnge tx	01-OCT-06	178	83
	S0622	Breast, Adv, 2 sched Dasatinib	15-MAR-07	135	57
	S0800	Brst,Neoadj nabPAC+/-Bev->AC+G	01-APR-10	160	56
	B39	Stg 0-2, whole vs partial RT	22-MAR-05	242	126
	C40302	Endocrine +/-1 Inhibition	22-SEP-06	96	53
	C40503	EndocrineTxCombo w/AntiVEGF Tx	22-MAY-08	77	40
	C40601	NeoAdj, Her-2+, Pac+Trast or Lap	08-DEC-08	82	48
	C40603	Carb/Bev+Neoadj Pac, then AC/EC	21-MAY-10	49	23
	C70301	QOLEmployInformCareCost Analysis	24-OCT-05	11	8
	E1105	Adv, Trastuzumab +/- Bev	21-NOV-07	130	45
	IBC24-02	Ovar Ftn suppress/premeno	04-AUG-03	194	103
	JMA27B	5yr Adj Anast vs Exemestrane	24-APR-06	127	39
	MA.32	Metformn vs Placebo	08-JUL-10	0	2
	N063D	ALTTO	15-FEB-08	277	134
	N0733	Her2+, Cap + Lap +/- IMC-A12	30-JUL-08	131	60
	PACCT-1	Assess of Ca Clinical Tests	24-APR-06	452	272
CC	S0715	ALC Taxane-induced neuropathy	15-SEP-09	281	103
GI	S0518	Carcinoid,Adv,Octreo/Alpha/Bev	01-DEC-07	150	64
	S0600	COLREC,MET,CHEMO+CETUX OR BEV	15-JUN-07	234	101
	S0713	Rect,Stg2-3,Ox/Cape/Cet+RT->SRG	01-FEB-09	92	29
	S0809	EHCC,Adj,Cape+Gem==>Cape+RT	01-DEC-08	163	70
	S0941	GallChol,Adv,Sorafenib/Erlotinib	15-APR-10	111	39
	C80405	GI,Met,FOLFOX/FIRI,Bev,Cetux	26-SEP-05	337	181
	C80702	Adj FOLFOX+Celecoxib or Placebo	22-JUN-10	0	39
	E1208	Chemo Soraf. in Unresect HCC	09-NOV-09	26	19
	E5202	Colon,Stg2,5FU/Leuc/Oxal +/- Bev	08-AUG-05	0	159
	R04	Rectum, Capecitabine vs 5FU	09-AUG-04	263	125
	R0848	Panc, Adj, Erlotinib v ChemoRT	08-DEC-09	0	54
GU	S0337	Blad, Instill Gem vs Saline	15-JUL-07	113	27
	C90202	Pros,Bone mets,Zoledronic acid	15-JAN-04	0	59
	C90203	Pros, Surgery +/- Neoadj Chemo	22-DEC-06	0	73
	C90601	Trans cell, blind bev vs placebo	07-AUG-09	0	81
	E2804	BeST Trial	21-MAR-08	0	100

Diseas	Study	Study Name	Open Date	Number of Active Institutions	Number of Current IRBs
GU	E2805	Renal, Adj Sunitib v Sorafinib	08-MAY-06	0	211
	E3805	CHAARTED	08-AUG-06	0	66
	PR11	Pros, Local, Watch vs Active Tx	15-JUL-07	0	18
	R0415	Hypofrac v Conv 3D-CRG/IMRT	24-APR-06	0	33
	R0521	AS+RT vs AS+RT+Chemo	22-DEC-05	0	57
	R0524	Pac + Trastuzumab vs Pac alone	08-DEC-06	0	34
GYN	S0904	GYN,OVAR,Doc +/- Vandetanib,II	15-MAR-10	99	34
LEUK	S9007	Cytogen. Studies in Leuk. Pts.	15-JUL-91	338	115
	S9910	Leuk Central Lab/Tissue Repos	15-APR-99	294	108
	S0805	Ph+ ALL, Dasatinib/CVAD +/- BMT	01-SEP-09	72	15
	S0919	Rel AML: Pravastatin+Ida+Ara-C	15-AUG-09	94	34
	C10403	ALL <30 yrs-Ped,Chemo. Regimen	15-JAN-08	114	48
	C10404	CLL, Flu/Rituxan combinations	15-MAR-09	94	54
	C10603	PKC 412, blinded, FLT3 AML	22-APR-08	121	64
	E1905	MDS/CMMoL/AML-TLD,Aza+/-MS-275	01-OCT-06	112	57
E2905	MDS, Len vs Len + Epo	09-FEB-09	127	80	
LUNG	S0424	Molecular Epidemiology NSCLC	01-OCT-05	284	125
	S0635	Bac, Stg IIIIB/IV Bev + OSI-774	15-JUL-07	187	53
	S0709	NSCLC, Adv, PRO+, OSI-774+-Chemo	01-DEC-08	137	52
	S0720	NSCLC,Stg I,ERCCL/RRM1 to Adj Tx	15-NOV-08	211	78
	S0722	Mesothelioma, RAD001	01-DEC-08	155	46
	S0802	ESCLC,Topotecan+/-AVE0005,PhII	15-MAY-09	190	80
	S0819	NSCLC, Adv, Chemo/Bev +/-Cet	15-JUL-09	289	129
	S0905	Mesothem,cediranib+chemo,PhI/II	15-MAR-10	2	3
	C140503	NSCL, Lobect v Sublobar resect	09-JUL-07	97	40
	C30610	SCLC, Thoracic RT	21-MAR-08	161	78
E1505	Stg IB-III A chemo +/- Bev	22-JUN-07	385	202	
LYMPH	S8819	Lymphoma Immunophenotyping	15-FEB-89	226	71
	S8947	Lymphoma Serum Repository	15-APR-90	233	81
	S9245	Relapsed Lymph Tissue Submis	15-MAR-93	94	29
	S0350	NHL, PEGS, Phase II	15-SEP-05	103	35
	S0801	NHL, Adv, CHOP-R + I-131 + RM	01-APR-09	128	33
	S0816	HD, Adv, PET-Adapted Therapy	01-JUL-09	170	72
	C50303	R-CHOP v EPOCH-R	15-SEP-06	93	60

Diseas Site	Study	Study Name	Open Date	Number of Active Institutions	Number of Current IRBs
LYMPH	C50604	Resp-Adapt Chemo Pos Emiss Tomo	22-JUL-10	0	1
	CTN0701	Relapsed follic, allo transplant	23-FEB-09	32	8
MELAN	S0826	Melan, Adv, SCH 727965, Ph II	01-JUL-09	186	74
	E1697	Melan, HDIFN vs Observation	15-OCT-02	256	101
MMYEL	S0115	Mel+PBSCT for High Risk MM+ALA	01-JAN-04	74	19
	S0120	Asympt Monoclonal Gammopathies	01-JUN-02	58	22
	S0309	MMYEL Specimen Repository	15-NOV-03	230	79
	S0777	MM, Len Dex +/- Bortezomib	01-APR-08	207	74
TM	S0711	Liver dysfunction PK, Dasatinib	15-OCT-08	9	10